Garwood is presently raising $3 million in a series B round and is engaged in another round of animal testing of its Biofilm Disruption Device (BDD), according to a University at Buffalo news release. Company officials plan to submit an application next year to U.S. FDA for de novo classification.
“Our goal is to eliminate the need for follow-up surgeries. We think we can wipe out infection-causing bacteria before trouble starts,” said Garwood Medical Devices CEO Wayne Bacon.
Get the full story on our sister site Medical Design & Outsourcing.